JP2020503265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503265A5 JP2020503265A5 JP2019527321A JP2019527321A JP2020503265A5 JP 2020503265 A5 JP2020503265 A5 JP 2020503265A5 JP 2019527321 A JP2019527321 A JP 2019527321A JP 2019527321 A JP2019527321 A JP 2019527321A JP 2020503265 A5 JP2020503265 A5 JP 2020503265A5
- Authority
- JP
- Japan
- Prior art keywords
- raav
- vector according
- pharmaceutical composition
- virus
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000007913 intrathecal administration Methods 0.000 claims description 8
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 claims description 5
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 claims description 5
- 229960001025 iohexol Drugs 0.000 claims description 5
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 5
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 claims description 3
- 208000006289 Rett Syndrome Diseases 0.000 claims description 3
- 229960004108 iobitridol Drugs 0.000 claims description 3
- YLPBXIKWXNRACS-UHFFFAOYSA-N iobitridol Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(NC(=O)C(CO)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I YLPBXIKWXNRACS-UHFFFAOYSA-N 0.000 claims description 3
- 229960000780 iomeprol Drugs 0.000 claims description 3
- NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 claims description 3
- 229960004647 iopamidol Drugs 0.000 claims description 3
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims description 3
- -1 iopentor Chemical compound 0.000 claims description 3
- 229960002603 iopromide Drugs 0.000 claims description 3
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims description 3
- 229960004537 ioversol Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000013608 rAAV vector Substances 0.000 claims 8
- 241000700605 Viruses Species 0.000 claims 7
- 239000002872 contrast media Substances 0.000 claims 6
- 239000013603 viral vector Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 230000008488 polyadenylation Effects 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108090000565 Capsid Proteins Proteins 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 101150083522 MECP2 gene Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 241000649044 Adeno-associated virus 9 Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022112657A JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| JP2024008380A JP2024045289A (ja) | 2016-11-17 | 2024-01-24 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423618P | 2016-11-17 | 2016-11-17 | |
| US62/423,618 | 2016-11-17 | ||
| PCT/US2017/062371 WO2018094251A1 (en) | 2016-11-17 | 2017-11-17 | Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112657A Division JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020503265A JP2020503265A (ja) | 2020-01-30 |
| JP2020503265A5 true JP2020503265A5 (enExample) | 2020-12-24 |
| JPWO2018094251A5 JPWO2018094251A5 (enExample) | 2022-04-13 |
| JP7106534B2 JP7106534B2 (ja) | 2022-07-26 |
Family
ID=62145776
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527321A Active JP7106534B2 (ja) | 2016-11-17 | 2017-11-17 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| JP2022112657A Pending JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| JP2024008380A Pending JP2024045289A (ja) | 2016-11-17 | 2024-01-24 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112657A Pending JP2022137210A (ja) | 2016-11-17 | 2022-07-13 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
| JP2024008380A Pending JP2024045289A (ja) | 2016-11-17 | 2024-01-24 | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11583564B2 (enExample) |
| EP (1) | EP3541429A4 (enExample) |
| JP (3) | JP7106534B2 (enExample) |
| KR (1) | KR102641846B1 (enExample) |
| CN (2) | CN110325219B (enExample) |
| AU (2) | AU2017362491B2 (enExample) |
| BR (1) | BR112019009834B1 (enExample) |
| CA (1) | CA3044291A1 (enExample) |
| CL (1) | CL2019001354A1 (enExample) |
| IL (2) | IL322146A (enExample) |
| MA (1) | MA46863A (enExample) |
| MX (1) | MX2019005874A (enExample) |
| SA (1) | SA519401806B1 (enExample) |
| SG (1) | SG10202105090WA (enExample) |
| WO (1) | WO2018094251A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11583564B2 (en) * | 2016-11-17 | 2023-02-21 | Nationwide Children's Hospital, Inc. | Intrathecal delivery of recombinant adeno-associated virus encoding Methyl-CpG binding protein 2 |
| IL274430B2 (en) | 2017-11-08 | 2025-01-01 | Novartis Gene Therapies Inc | Means and method for preparing viral vectors and their uses |
| EP3801638A1 (en) | 2018-06-08 | 2021-04-14 | Novartis AG | Cell-based assay for measuring drug product potency |
| EA202192160A1 (ru) * | 2019-02-04 | 2021-11-17 | Рисерч Инститьют Эт Нэшнуайд Чилдрен'С Хоспитал | Доставка полинуклеотида cln3 с помощью аденоассоциированного вируса |
| US20220389453A1 (en) * | 2019-10-18 | 2022-12-08 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of disorders associated with the irf2bpl gene |
| WO2021102435A1 (en) * | 2019-11-22 | 2021-05-27 | Research Institute At Nationwide Children's Hospital | Materials and methods for treatment of disorders associated with the ighmbp2 gene |
| EP4323010A1 (en) | 2021-04-13 | 2024-02-21 | Research Institute at Nationwide Children's Hospital | Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery |
| WO2024235164A1 (zh) * | 2023-05-15 | 2024-11-21 | 上海金珂博生物技术有限公司 | 一种Rett综合症的基因治疗 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| DE69433922T2 (de) | 1993-11-09 | 2005-07-28 | Medical College Of Ohio, Toledo | Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren |
| AU688428B2 (en) | 1993-11-09 | 1998-03-12 | Johns Hopkins University, The | Generation of high titers of recombinant AAV vectors |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| RU2273645C9 (ru) | 1994-08-17 | 2006-11-27 | Дзе Рокефеллер Юниверсити | Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| EP0796339A1 (en) | 1994-12-06 | 1997-09-24 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| CA2230655C (en) | 1995-08-30 | 2008-06-17 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| AU715543B2 (en) | 1995-09-08 | 2000-02-03 | Genzyme Corporation | Improved AAV vectors for gene therapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| IL128779A0 (en) | 1996-09-06 | 2000-01-31 | Univ Pennsylvania | Method for recombinant adeno-associated virus-directed gene therapy |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| DK1944362T3 (en) | 1997-09-05 | 2016-01-25 | Genzyme Corp | Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| GB9916702D0 (en) | 1999-07-16 | 1999-09-15 | Cantab Pharma Res | Virus vectors and preparations and their use |
| CA2406743A1 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| PT2573170T (pt) | 2001-12-17 | 2018-03-26 | Univ Pennsylvania | Sequências de um vírus adenoassociado (aav) de serotipo 9, vetor contendo as mesmas, e suas utilizações |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| JP5830213B2 (ja) * | 2004-02-17 | 2015-12-09 | ザ ホスピタル フォー シック チルドレン | Ｍｅｃｐ２ｅ１遺伝子 |
| EP3146982B1 (en) * | 2006-10-03 | 2019-08-21 | Genzyme Corporation | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
| KR20100113112A (ko) | 2008-01-15 | 2010-10-20 | 아보트 러보러터리즈 | 개선된 포유동물 발현 벡터 및 이의 용도 |
| US20090246768A1 (en) | 2008-02-15 | 2009-10-01 | Sawalha Amr H | Predicting and Diagnosing Patients With Autoimmune Disease |
| US11219696B2 (en) | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
| US9415121B2 (en) * | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| JP6754361B2 (ja) * | 2014-12-16 | 2020-09-09 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 若年型バッテン病のための遺伝子療法 |
| US11583564B2 (en) * | 2016-11-17 | 2023-02-21 | Nationwide Children's Hospital, Inc. | Intrathecal delivery of recombinant adeno-associated virus encoding Methyl-CpG binding protein 2 |
| BR112019025732A2 (pt) * | 2017-06-06 | 2020-06-30 | University Of Massachusetts | vetores de aav auto-reguladores para expressão segura de mecp2 na síndrome de rett |
-
2017
- 2017-11-17 US US16/461,837 patent/US11583564B2/en active Active
- 2017-11-17 CN CN201780072105.XA patent/CN110325219B/zh active Active
- 2017-11-17 SG SG10202105090WA patent/SG10202105090WA/en unknown
- 2017-11-17 MA MA046863A patent/MA46863A/fr unknown
- 2017-11-17 MX MX2019005874A patent/MX2019005874A/es unknown
- 2017-11-17 WO PCT/US2017/062371 patent/WO2018094251A1/en not_active Ceased
- 2017-11-17 CN CN202410270436.6A patent/CN118490845A/zh active Pending
- 2017-11-17 KR KR1020197017104A patent/KR102641846B1/ko active Active
- 2017-11-17 EP EP17872045.4A patent/EP3541429A4/en active Pending
- 2017-11-17 AU AU2017362491A patent/AU2017362491B2/en active Active
- 2017-11-17 JP JP2019527321A patent/JP7106534B2/ja active Active
- 2017-11-17 IL IL322146A patent/IL322146A/en unknown
- 2017-11-17 CA CA3044291A patent/CA3044291A1/en active Pending
- 2017-11-17 BR BR112019009834-8A patent/BR112019009834B1/pt active IP Right Grant
-
2019
- 2019-05-16 IL IL266678A patent/IL266678B2/en unknown
- 2019-05-17 CL CL2019001354A patent/CL2019001354A1/es unknown
- 2019-05-17 SA SA519401806A patent/SA519401806B1/ar unknown
-
2022
- 2022-07-13 JP JP2022112657A patent/JP2022137210A/ja active Pending
-
2023
- 2023-01-02 US US18/149,151 patent/US12357663B2/en active Active
- 2023-04-28 AU AU2023202598A patent/AU2023202598A1/en active Pending
-
2024
- 2024-01-24 JP JP2024008380A patent/JP2024045289A/ja active Pending
-
2025
- 2025-06-20 US US19/244,103 patent/US20250312400A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503265A5 (enExample) | ||
| JP2019513794A5 (enExample) | ||
| JP2020510428A5 (enExample) | ||
| JP2020514286A5 (enExample) | ||
| JP2018537984A5 (enExample) | ||
| JP7106534B2 (ja) | メチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルスの髄腔内送達 | |
| RU2018136611A (ru) | Генная терапия для лечения гемофилии a | |
| JP2017512466A5 (enExample) | ||
| JP2021510528A (ja) | 遺伝子治療のための修飾ｒＡＡＶキャプシドタンパク質 | |
| TW201629225A (zh) | 第九因子基因療法 | |
| JP2018531609A5 (enExample) | ||
| JP2017531652A (ja) | Ａａｖに基づく遺伝子治療 | |
| JP2018506261A5 (enExample) | ||
| JP2020519292A5 (enExample) | ||
| JP2023040219A5 (enExample) | ||
| KR20210153069A (ko) | 섬유아세포 성장 인자 23 관련 저인산혈증성 질환의 유전자 요법 | |
| JP2020510433A5 (enExample) | ||
| JP2006511212A5 (enExample) | ||
| CN116457466A (zh) | 用于抑制α-突触核蛋白聚集的组合物和方法 | |
| CA3146364A1 (en) | One-step gene therapy for duchenne muscular dystrophy via gene replacement and anti-inflammation | |
| US20240293577A1 (en) | Methods and means for the prevention and/or treatment of hemophilic arthropathy in hemophilia | |
| EP4198046A1 (en) | Alpha-sarcoglycan gene transfer increase using modified itr sequences | |
| TW202246505A (zh) | 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途 | |
| OA21369A (en) | Codon-optimized nucleic acid encoding the fix protein. | |
| WO2023015269A1 (en) | Aqp1 gene therapy to prevent radiation induced salivary hypofunction |